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DBackground: Preexisting valve pathology is common in patients with end-stage heart failure undergoing left
ventricular assist device (LVAD) placement. The indications and subsequent benefits of performing valvular
procedures in these patients are unclear. The objective of this study was to determine the impact of performing
concurrent surgical valve procedures in a large cohort of patients receiving LVADs.
Methods:One thousand one hundred six patients received theHeartMate II (HMII) LVAD in the bridge to transplant
(n ¼ 470) and destination therapy (n ¼ 636) clinical trials. Of these, 374 patients (34%) had concurrent cardiac
surgery procedures as follows: 242 patients (21%) with 281 concurrent valve procedures (VP) (aortic 80, mitral 45,
and tricuspid 156), and 641 patients had only HMII LVAD. The focus of this study was to determine the clinical
outcomes of patients undergoing HMIIþ VP compared with those who received HMII alone.
Results: Patients undergoing HMII þ VP were significantly older, had higher blood urea nitrogen levels and
central venous pressure, and decreased right ventricular stroke work index; intraoperatively, the median
cardiopulmonary bypass times were also longer. The unadjusted 30-day mortality was significantly higher in
patients undergoing HMII þ VP (10.3% vs 4.8% for LVAD alone, P ¼ .005). Subgroup analysis of individual
VPs showed that higher mortality occurred in patients with HMII plus 2 or more VPs (13.5%, P¼ .04) followed
by trends for increased mortality with HMII plus mitral alone (11.5%, P¼NS), HMII plus aortic alone (10.9%,
P¼NS), and HMII plus tricuspid (8.9%,P¼NS) procedures. Of these various groups, only patients undergoing
HMII þ isolated aortic VP (P ¼ .001) and HMII þ multiple VPs (P ¼ .046) had significantly worse long-term
survival compared with patients undergoing HMII alone. Right heart failure and right ventricular assist device
use was increased in patients undergoing VPs, but there was no difference in the incidence of bleeding or stroke.
Conclusions: Patients frequently require concurrent VPs at the time of LVAD placement; these patients are
sicker and have higher early mortality. Furthermore, right ventricular dysfunction is increased in these patients.
Further studies to develop selection criteria for concurrent valve interventions are important to further improve
clinical outcomes. (J Thorac Cardiovasc Surg 2014;147:581-9)The recent advent of continuous-flow left ventricular assist
devices (LVADs) has had an important impact on survival
and quality of life for patients once considered to have
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The Journal of Thoracic and Cawith advanced stage heart failure refractory to medical
therapy are being supported by LVADs as a bridge to
heart transplant (BTT) or for destination therapy (DT).
Support with an LVAD has become standard therapy in
most advanced heart failure programs because of the
increased acceptance of the therapy after positive clinical
trial results.3,4
The US Food and Drug Administration commercially
approved the HeartMate II (HMII) continuous-flow LVAD
(Thoratec Corporation, Pleasanton, Calif) for BTT in
2008 and for DT in 2010.1,2 Survival for the BTT
indication has steadily improved since then and is
approaching that of heart transplantation.5 In 2010,
outcome data from the postapproval study of commercial
use conducted through the INTERMACS Registry showed
a further increase in 1-year survival to 85% in the first
group of patients.6 Results for HMII LVAD as DT also
continue to improve.7
It is well recognized that coexisting heart valve disease
might complicate the placement and efficient functioning
of LVADs. However, significantly abnormal valverdiovascular Surgery c Volume 147, Number 2 581
Abbreviations and Acronyms
AI ¼ aortic insufficiency
BTT ¼ bridge to heart transplant
BUN ¼ blood urea nitrogen
CVP ¼ central venous pressure
DT ¼ destination therapy
HMII ¼ HeartMate II
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
RA ¼ right atrial
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
RVSWI ¼ right ventricular stroke work index
TR ¼ tricuspid regurgitation
VP ¼ valve procedure
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Dpathophysiology can also occur after LVAD placement and
can seriously interfere with its benefits.8 Native mitral and
tricuspid valve disease is certainly more common in the pa-
tients with heart failure who are most likely to undergo
LVAD placement. Nonetheless, aortic valves are much
more likely to undergo structural changes and lead to
abnormal pathophysiology in patients both during and
after LVAD placement. The indications and subsequent
benefits of performing valvular procedures in these patients
are unclear.
The objective of this study was (1) to determine the
impact of performing concurrent surgical valve procedures
in a large cohort of patients receiving LVADs on short-term
and long-term survival, and (2) postoperative morbidity in
this patient population.PATIENTS AND METHODS
Patients
This study is a retrospective review of 1106 patients supported by the
HMII LVAD as BTT and DT during the clinical trial. Patients receiving
the HMII as an exchange for a previous HeartMate XVE or as
compassionate use were excluded from this analysis. The trial group
included 470 patients undergoingBTTand 636 undergoingDTat 44 centers
who were enrolled into the HMII clinical trial fromMarch 2005 to January
2010. All patients met the study inclusion criteria and gave informed
consent as approved by the Institutional Review Boards at the participating
institutions.
Data Collection
For this study, the trial data were obtained from the study sponsor
(Thoratec Corporation). The overall trial results have been published
previously.1,2,4
End Points
The outcome end points analyzed in this study were overall survival
from the LVAD implant, ongoing LVAD support, transplant, device
removal after myocardial recovery, and death. Patients were divided into582 The Journal of Thoracic and Cardiovascular Surg2 groups: (1) patients who underwent HMII implantation alone without
any concurrent procedures (HMII alone); and (2) patients who underwent
concurrent valve procedures (HMII þ VP). Adverse events occurring in
these patients up to July 2012 were included (definitions are included in
the supplementary material in Ref. 2), are also presented.
HMII LVAD
The pump used in this study was the HMII LVAD, which is a
continuous-flow device consisting of an internal axial flow blood pump
with a percutaneous lead that connects the pump to an external system
driver and power source, which has been described previously.3
The pump contains an internal rotor with helical blades that curve around
a central shaft. When the rotor spins on its axis, kinetic energy is imparted
to the blood, which is drawn continuously from the left ventricular (LV)
apex through the pump and into the ascending aorta. The pump has an
implant volume of 63 mL and generates up to 10 L/min of flow at a
mean pressure of 100 mm Hg.
Surgical Implantation
Surgical implantation of the HMII LVAD was conducted according to
the instructions for use of the HMII LVAD. The need for valvular
procedures and the types and methods of valvular procedures used were
at the investigator’s discretion, and followed each centers’ standard of care.
Postimplant Follow-up
After device implantation, a standardized antithrombotic medical
regimen was implemented with initiation of heparin followed by transition
to warfarin as well as aspirin. Postoperative medical management,
including inotrope, antiarrhythmic, and heart failure therapy, was
performed according to each investigator’s preference and usual practice.
Patients were followed up until July, 2012.
Statistical Analysis
All statistical comparisons were 2-sided. Data are given as the
mean þ standard deviation, or when appropriate, the median and range
are provided. Discrete variables are given as a percentage. Differences in
continuous variables between the study groups were determined with the
t test or the nonparametric Mann-Whitney U test (when not normally
distributed). The Fisher exact test was used to determine differences in
categorical variables. Survival analysis was performed by using the
Kaplan-Meier method with censoring for ongoing LVAD support in July,
2012, or device explantation for transplantation or recovery. Differences
in survival were determined using the log-rank test. A multivariable risk
factor analysis of death in this patient population was performed and
published recently.9 The analysis led to the development of the HMII
risk score, which was validated in the same study for predicting 90-day
mortality after HMII implantation. A Cox proportional hazards regression
was performed to test the differences between patients with the HMII
without any concurrent procedures, and (1) patients with the HMII who
underwent a valvular procedure, (2) patients with the HMII who underwent
an aortic procedure only, adjusted for the HMII risk score. Statistical
analyses were performed using SAS software (SAS Institute Inc.,
Cary, NC).RESULTS
Baseline Characteristics
There were a total of 1106 patients included in this
study; 470 patients received the HMII LVAD as BTT and
636 patients as DT. Figure 1 shows the overall breakdown
of patients investigated in this study. Of these, 641 patients
had no concurrent procedures and 242 patients hadery c February 2014
FIGURE 1. Patient cohort used in this study. HMII, HeartMate II; BTT, bridge to heart transplant; DT, destination therapy.
TABLE 1. Overview of concurrent cardiac procedures performed
during HMII implantation
Summary of concurrent cardiac
procedures Number of patients
Patients with valvular procedures 242
Only tricuspid 124
Only aortic 55
Only mitral 26
Tricuspid þ aortic 18
Tricuspid þ mitral 12
Aortic þ mitral 5
Tricuspid þ mitral þ aortic 2
Patent foramen ovale closure 61
Removal of LV thrombus 8
LV aneurysm resection/repair 5
Insert ICD/repair ICD 8
CABG 22
RF ablation 3
RA thrombectomy 4
Lysis of cardiac adhesions 3
HMII, HeartMate II; LV, left ventricular; ICD, implantable cardioverter defibrillator;
CABG, coronary artery bypass graft; RF, radiofrequency; RA, right atrial.
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Dconcurrent valvular procedures. One hundred thirty-two
patients receiving nonvalvular procedures were excluded
(these included closure of patent foramen ovale, n ¼ 61;
coronary artery bypass grafting, n ¼ 22; removal of an
LV thrombus, n ¼ 8; and LV aneurysm repair, n ¼ 5).
Of the 242 patients undergoing concurrent valvular
procedures, 124 had isolated tricuspid valve procedures,
55 had isolated aortic valve procedures, 26 had
isolated mitral valve procedures, and the remaining 37
had combinations of tricuspid, aortic, and mitral valve
procedures (Table 1).
The baseline characteristics for the 641 HMII alone
patients and 242 HMII þ VP patients are shown in
Table 2. Demographics were similar, except that patients
undergoing HMII þ VP were significantly older (61  14
vs 58 14 years, P<.001), had higher blood urea nitrogen
level (BUN) (37.4 27.2 vs 31.3 17.5 mg/dL, P¼ .006),
central venous pressure (CVP) (13.8  6.6 vs 12.3  6.4
mm Hg, P ¼ .003) and CVP/pulmonary capillary wedge
pressure (PCWP) (0.56  0.24 vs 0.52  0.38, P ¼ .005),
and decreased right ventricular stroke work index (RVSWI)
(512  280 vs 576  303, P ¼ .008). However, there was
significantly increased inotrope use in the HMII alone group
(85% vs 77%, P ¼ .005). Despite several variables
reflecting that patients in the HMIIþVP group were sicker,
there was no difference in the DT risk score (P ¼ .147) or
HMII risk score (P ¼ .302) between the 2 groups.
Intraoperatively, mean cardiopulmonary bypass times
were also longer for the HMII þ VP group (135  56 vs
93  46 minutes, P<.001) as well as the median hospital
length of stay (26 vs 23 days, P ¼ .05) (Table 3).
Survival
Short-term survival. The unadjusted 30-daymortality was
significantly higher in patients who underwent HMII þ VPThe Journal of Thoracic and Cacompared with the group who received HMII alone (10.3%
vs 4.8%, P ¼ .005). Subgroup analysis of individual valve
procedures showed that the higher 30-daymortality occurred
in patients with HMII plus 2 or more valve procedures
(13.5%, P ¼ .04), followed by HMII plus mitral alone
(11.5%, P ¼ .141), HMII plus aortic alone (10.9%,
P ¼ .063), and HMII plus tricuspid alone (8.9%, P ¼ .084)
procedures. However, 180-day mortality was only signifi-
cantly higher for patients undergoing isolated aortic valve
procedures (29.1% vs 15.9%, P ¼ .023). Table 4 shows the
30-day and 180-day mortality for the various groups. The
30-day and 180-day mortality for HMII þ patent foramen
ovale closure is similar to the HMII alone group.rdiovascular Surgery c Volume 147, Number 2 583
TABLE 2. Comparison of baseline characteristics between patients
receiving HMII alone versus HMII þ VP
HMII alone
(N ¼ 641)
HMII þ VP
(N ¼ 242)
P
value
Age, y 58  14 61  14 <.001
Female, no. (%) 142 (22) 48 (20) .205
Ischemic, no. (%) 336 (52) 122 (50) .598
Mechanical ventilation, no. (%) 31 (5) 7 (3) .265
IABP, no. (%) 188 (29) 62 (26) .315
Inotrope use, no. (%) 546 (85) 186 (77) .005
DT, no. (%) 364 (57) 152 (63) .109
CVP, mm Hg 12.3  6.4 13.8  6.6 .003
PVR 3.22  1.75 3.43  1.85 .147
PCWP, mm Hg 24.6  8.8 24.8  7.7 .541
RVSWI 576  303 512  280 .008
CVP/PCWP 0.52  0.38 0.56  0.24 .005
INR 1.33  0.62 1.37  0.69 .290
Creatinine, mg/dL 1.45  0.52 1.51  0.59 .331
Cardiac index, L/min/m2 2.03  0.64 1.97  0.59 .560
BUN, mg/dL 31.3  17.5 37.4  27.2 .006
AST, IU/L 57  156 54  110 .650
L-M score 9.72  5.38 10.4  5.4 .147
HMII risk score 1.77  1.11 1.85  1.14 .302
HMII, HeartMate II; VP, valve procedure; IABP, intra-arterial balloon pump;
DT, destination therapy; CVP, central venous pressure; PVR, pulmonary vascular
resistance; PCWP, pulmonary capillary wedge pressure; RVSWI, right ventricular
stroke work index; INR, international normalized ratio; BUN, blood urea nitrogen;
AST, aspartate aminotransferase; L-M, Lietz-Miller score.
TABLE 4. Comparison of short-term mortality between patients
receiving HMII alone versus HMII þ VP
Patients N
30-day
mortality, n (%)
180-day mortality,
n (%)
HMII alone 641 31 (4.8) 102 (15.9)
HMII þ VP 242 25 (10.3)y 51 (21.0)
Aortic only 55 6 (10.9) 16 (29.1)*
Mitral only 26 3 (11.5) 6 (23.1)
Tricuspid only 124 11 (8.9) 21 (16.9)
2 or more valves 37 5 (13.5)* 8 (22)
HMII þ other 91 8 (8.9) 15 (16.7)
HMII, HeartMate II; VP, valve procedure. *P<.05; yP<.01 relative to no concurrent
procedures.
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various groups is shown in Figure 2 (HMII alone vs HMII
þ VP) and Figure 3 (HMII alone vs HMII þ isolated aortic
valve procedure [Figure 3, A], HMIIþ isolated mitral valve
procedure [Figure 3, B], HMII þ isolated tricuspid valve
procedure [Figure 3, C], and HMII þ multiple valve
procedures [Figure 3, D]). Of these various groups, only
HMII þ isolated aortic valve procedure (P ¼ .001) and
HMII þ multiple valve procedures (P ¼ .046) had
significantly worse long-term survival compared with
HMII alone.
A Cox proportional hazards regression was performed to
test the differences between patients who underwent HMIITABLE 3. Comparison of cardiopulmonary bypass time and initial
hospital length of stay between patients receiving HMII alone versus
HMII þ VP
Variable of interest
HMII alone
(N ¼ 641)
HMII þ VP
(N ¼ 242)
P
value
Cardiopulmonary bypass time
(min)
Mean  standard deviation 93  46 137  56 <.001
Median (min, max) 88 (10, 690) 126 (53, 388) <.001
Length of stay (d)
Mean  standard deviation 31  23 35  32 .047
Median 23 26 .045
HMII, HeartMate II; VP, valve procedure.
584 The Journal of Thoracic and Cardiovascular Surgwithout any concurrent procedures, and (1) patients who
underwent HMII and a valvular procedure, (2) patients
who underwent HMII and an aortic procedure only;
adjusted for the HMII risk score. Differences in survival
between the 2 groups persisted even after adjusting for
baseline HMII risk score. For HMII no procedures versus
valve procedures, the unadjusted P value was .004; the
P value adjusted for HMII risk score was .006. For HMII
no procedures versus isolated aortic valve procedures
only, the unadjusted P value was .001; the P value adjusted
for HMII risk score was .002.Adverse Events
Table 5 shows a comparison of early adverse events
(<30 days) between the 2 groups of patients (HMII alone
vs HMII þ VP) in the first 30 days. Right heart failure
and right ventricular assist device (RVAD) use was
increased in VP patients, but there was no difference in
other early adverse events including bleeding or stroke.
Table 6 shows a comparison of all the adverse events
between the 2 groups. Bleeding requiring packed red bloodFIGURE 2. Kaplan-Meier survival of patients undergoing HMII alone
versusHMIIþ concurrent valve procedures.HMII, HeartMate II;VP, valve
procedure.
ery c February 2014
FIGURE 3. Kaplan-Meier survival of patients undergoing HMII alone and (A) isolated aortic valve procedure (AVP); B, isolated mitral valve procedure
(MVP); C, isolated tricuspid valve procedure (TVP); and D, multiple valve procedures. HMII, HeartMate II.
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patients undergoing HMII þ VP.Aortic Valve
Fifty-five patients underwent isolated aortic valve
procedures and 25 patients underwent aortic valveTABLE 5. Adverse events in the first 30 days
Adverse event
within first 30 days
HMII alone
(N ¼ 641), n (%)
HMII þ VP
(N ¼ 242), n (%) P
Bleeding 311 (49) 126 (52) .366
Bleeding requiring surgery 108 (17) 46 (19) .487
Right heart failure 85 (13) 48 (20) .02
RVAD 9 (1.4) 22 (9.1) <.001
Renal dysfunction/failure 36 (6) 20 (8) .164
Ischemic stroke 15 (2.3) 4 (1.7) .614
Hemorrhagic stroke 8 (1.3) 2 (0.8) .736
HMII, HeartMate II; VP, valve procedure; RVAD, right ventricular assist device.
The Journal of Thoracic and Caprocedures in addition to other valve procedures, resulting
in a total of 80 patients with aortic valve procedures.
Compared with the patients who underwent HMII
implantation alone, the patients who underwent isolated
concurrent aortic valve procedures were significantly older
(66  11 vs 58  14 years, P<.001), a lower proportion
were on inotropes (71% vs 85%, P ¼ .011), a higher
proportion were on DT (71% vs 57%, P ¼ .046), and
they had a higher HMII risk score (1.99  0.82 vs 1.85 
1.14, P ¼ .038). Of the 80 patients undergoing concurrent
aortic valve procedures, 18 had aortic valve repair, 32 had
aortic valve closure, and 30 had aortic valve replacement.
Thirty-day mortality was lowest for aortic valve closure at
6.3% (2/32), followed by aortic valve replacement at
13% (4/30) and aortic valve repair at 18% (3/18). As
seen in Figure 3, A, patients undergoing LVAD þ isolated
aortic valve procedures had worse 1- and 2-year survival
compared with LVAD alone (57% and 43% vs 75%
and 64% at 1 and 2 years, respectively, P ¼ .001).rdiovascular Surgery c Volume 147, Number 2 585
TABLE 6. Comparison of all adverse events
Adverse event
HMII alone
(N ¼ 641), n (%)
HMII alone
(1118.8 patient-years)
(events rate)
HMII þ VP
(N ¼ 242), n (%)
HMII þ VP
(396.04 patient-years)
(event rate) P
Bleeding requiring PRBC 429 (67) 1165 (1.04) 173 (71) 589 (1.49) <.001
Bleeding requiring reexploration 133 (21) 150 (0.13) 50 (21) 61 (0.15) 1.000
Sepsis 160 (25) 262 (0.23) 62 (26) 96 (0.24) .795
Any device-related infection 179 (28) 350 (0.31) 56 (23) 91 (0.23) .019
Cardiac arrhythmias 346 (54) 627 (0.56) 128 (53) 190 (0.48) .125
Renal failure 71 (11) 72 (0.06) 30 (12) 33 (0.08) .635
Right heart failure 125 (20) 142 (0.13) 56 (23) 60 (0.15) .282
RVAD 12 (2) N.A. 22 (9) N.A. <.001
Ischemic stroke 58 (9) 63 (0.06) 13 (5) 15 (0.04) .174
Hemorrhagic stroke 53 (8) 58 (0.05) 17 (7) 18 (0.05) .634
Other neurologic events 101 (16) 121 (0.11) 43 (18) 52 (0.13) .269
Hemolysis 32 (5) 34 (0.03) 12 (5) 20 (0.05) .075
HMII, HeartMate II; VP, valve procedure; PRBC, packed red blood cells; RVAD, right ventricular assist device.
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survival was still significantly lower for patients undergoing
aortic valve procedures (P ¼ .002).Tricuspid Valve
One hundred twenty-four patients underwent an isolated
tricuspid valve procedure and 32 patients underwent a
tricuspid valve procedure in addition to other valve
procedures. Compared with patients undergoing HMII
implantation alone, patients undergoing HMIIþ an isolated
tricuspid valve procedure had significantly higher BUN
(39.7  31.2 vs 31.3  17.5 mg/dL, P ¼ .008), CVP
(14.6  6.8 vs 12.3  6.4 mm Hg, P ¼ .002), CVP/PCWP
ratio (0.59 0.24 vs 0.52 0.38, P¼ .003), and decreased
RVSWI (482  289 vs 576  303, P ¼ .001). Of the
156 tricuspid valve procedures, 137 were tricuspid valve
repairs and 19 were valve replacements.
Although the patients undergoing tricuspid valve
procedures were sicker, there was no difference in both
short- and long-term survival compared with patients
undergoing LVAD alone (Figure 3, C, and Table 4).
However, patients undergoing LVAD þ tricuspid valve
procedures had a significantly higher incidence of right
ventricular (RV) failure (27.4% vs 19.5%, P ¼ .053), and
RVAD use after LVAD placement (9.7% vs 1.9%,
P<.001).DISCUSSION
Cardiac transplantation remains the gold standard for
therapy for end-stage heart failure. However, a decreasing
cardiac donor pool and persistent morbidity with cardiac
transplantation limits the wider use of this therapy. A major
obstacle to the success of long-term support with a
ventricular assist device is the ability of the native heart
in end-stage heart failure with a range of preexisting
valvular pathologies, to withstand the hemodynamic586 The Journal of Thoracic and Cardiovascular Surgchanges occurring during prolonged mechanical circulatory
support.Aortic Valve
One unanticipated complication of LVAD therapy has
been the development of de novo aortic valve lesions
leading to commissural fusion, aortic stenosis, and
incompetence.10,11 Aortic commissural fusion is a
remodeling process in which fibrous tissue is deposited at
the commissures of the coapted leaflets, adhering them
together and preventing complete opening. Equally
significant is the risk for preexisting aortic insufficiency
(AI) to worsen during the period of LVAD support.
Several recent studies have demonstrated that patients
supported with a continuous-flow device have more rapid
progression of AI relative to pulsatile flow devices. In these
studies, a larger aortic root diameter, higher pump speeds,
older age, and a closed aortic valve were risk factors
associated with greater progression of AI.12-15
With the potential forAI toworsenwithLVADsupport, it is
standard of care for AI to be corrected during LVAD
implantation. Intraoperative transesophageal echocardio-
graphy is the ideal way to diagnose and quantify the degree
of AI although the degree might be underestimated with
reduced afterload when the patient is under general
anesthesia. However, the degree of AI needed to be present
to warrant surgical correction at the time of LVAD implanta-
tion is unclear. Most agree that moderate AI should be
corrected; lesser degrees of AI such as mild to moderate AI
should be given consideration in patients on DT as well as
patients on BTT who might have a prolonged wait time for
transplantation.8 None of the studies with continuous-flow
devices that showed an increased incidence of late AI
reported an increase inmortality in this group of patients.12-15
The various options mentioned in the literature to treat AI
before LVAD placement have included medical careery c February 2014
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diuretics), closure of the native valve (with sutures), valve
replacement with a bioprosthetic valve, or patch closure
of the aortic/LV outflow tract.16-19 Recently, there have
been a few reports of closure of the aortic valve with
transcatheter aortic valve therapy in LVAD recipients
developing late AI. The optimal method of treating AI
remains unclear. In this study, the aortic valve procedures
were distributed between aortic valve replacement,
closure, and repair. Unfortunately, the reasons for the use
of each particular technique are unknown and individual
surgeons used their judgment to decide which technique
to use. Until recently, the best technique to treat AI at the
time of LVAD placement was believed to be replacing the
native valve with a bioprosthetic valve. However,
numerous reports of fusion of the leaflets of the
bioprosthetic valve, along with the longer ischemic time
during surgery, have significantly reduced enthusiasm for
that technique.16 Aortic valve repair seems to be a shorter
and easily reproducible procedure involving oversewing
the incompetent aortic valve with a purse-string pledgetted
suture. At this time, the effect of central aortic valve closure
on long-term aortic valve function (>2 years) as well as
durability of the repair with continuous-flow devices
remains to be determined, especially with regard to the
long-term durability that has been demonstrated with these
devices. Small single-center series have shown that the
single-suture technique provides a durable result for at least
2 years.17 With this technique, the aortic valve is still able to
open during cardiac ejection, allowing for some washing of
the aortic outflow tract and diminishing the risk of thrombus
formation. However, if there are concerns regarding the
durability of this repair (eg, if the leaflet tissue is thin
and fenestrated), then direct closure of the valve by
oversewing the edges of all 3 leaflets (with felt strips) can
also be done.
In this present study, patients undergoing aortic valve
procedures had higher HM II risk scores. Despite
adjusting for this higher risk score, this group had a
worse survival compared with the HMII alone group,
primarily as a result of higher early mortality. There
were no differences in key adverse events between the
2 groups, especially right heart failure and stroke. It is
possible that the need for aortic crossclamping and
cardioplegic arrest (which is only definitely needed for
the aortic valve group compared with tricuspid and
mitral procedures, which may be done with a beating
heart) contributes to the overall complexity of the
procedure and therefore to increased early mortality.
Similar to this study, 1 single-center study showed
increased early mortality with aortic valve repair;
the cause of the increased mortality could not be
explained by the aortic valve procedure alone.17 In
contrast, smaller single-center studies have shown eitherThe Journal of Thoracic and Caequivalent or improved survival in selected patients
undergoing aortic valve closure.18,19
Tricuspid Valve
RV dysfunction is often associated with tricuspid
valve annular dilatation and tricuspid regurgitation (TR);
both severe TR and significant RV dysfunction have been
identified as predictors of increased mortality after LVAD
placement.20 Several previous studies were designed to
help predict those patients at high likelihood of developing
RV failure after LVAD. Unfortunately, the complex
pathophysiology of RV failure, which could potentially be
related to RV myocardial dysfunction, interventricular
dependence, and RV afterload, has led to inconsistencies
in predicting risk factors for RV dysfunction. Kormos and
colleagues21 studied the risk factors for RV failure in a large
cohort of almost 500 patients receiving the HMII
continuous-flow LVAD as part of a multicenter clinical trial.
In that study, the following variables were predictive of RV
failure: a CVP/PCWP ratio greater than 0.63, the need for
preoperative ventilator support and a BUN level greater
than 39 mg/dL. Additional variables that were significant
by univariate analysis included an increased white blood
cell count, increased CVP, and decreased RVSWI. Many
of the latter risk factors were seen in the cohort of patients
in our study who underwent concomitant tricuspid valve
procedures.
It is well known that after HMII implantation, there is a
trend toward a reduction in TR severity as LV loading
conditions improve.22 This finding suggests that TR
severity of moderate grade or less would not need to be
corrected by either tricuspid valve repair or replacement
at the time of HMII implantation, although this would
need to be confirmed in larger prospective studies. Other
single-center investigators have shown that the presence
of moderate or severe TR at the time of LVAD placement
predicted an increased risk of RV failure after LVAD.23,24
It remains unclear at this time whether to intervene
surgically on TR in all patients undergoing only LVAD
placement. However, some investigators do practice a
more aggressive approach to tricuspid valve annuloplasty
in patients undergoing LVAD placement.25-28 They
suggest that the diminished RV function requires an
increased RVend-diastolic pressure to maintain comparable
forward flow; this increased RV end-diastolic pressure can
cause tricuspid valve chordal tethering and worsen TR.
In this present study, there was no difference in survival
between patients undergoing concomitant tricuspid valve
procedures at the time of LVAD implant compared with
LVAD alone, despite these patients having several described
risk factors for RV failure. Despite the favorable survival
results, they had an increased risk of postoperative RV
failure and RVAD use. These results mirror those of several
single-center studies that demonstrate either a benefit orrdiovascular Surgery c Volume 147, Number 2 587
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Dequivalent survival with tricuspid valve repair in
patients with moderate or greater TR undergoing LVAD
placement.25-28
Limitations
The present study has several limitations that are
important in the interpretation of the data. The study was
nonrandomized with no real risk-adjusted group for direct
comparison. Some important variables that were not
examined in this study, but could potentially influence
surgical decision making, include the lack of data on
baseline echocardiographic parameters that would have
influenced the decision to intervene on valvular abnorma-
lities at the time of LVAD implant. As mentioned earlier,
the reasons for the use of each particular technique
(repair vs replacement) are unknown and individual
surgeons used their judgment to decide when to intervene
as well as which technique to use. Furthermore, the number
of mitral valve procedures was too small to allow for further
statistical analysis for this subgroup. Nevertheless, a major
strength of this study was the large number of patients
undergoing LVAD implant at experienced centers in the
framework of a clinical trial with strict inclusion and
exclusion criteria.
In conclusion, patients frequently require concurrent
valve procedures at the time of LVAD placement;
these patients are sicker and have higher early mortality.
The likelihood exists that the underlying cardiac sequelae
of valvular heart disease rather than the procedures
themselves may be responsible for the added risk in these
patients. It is clear that the difference in survival between
HMII plus valve procedures versus HMII alone is driven
by the addition of aortic valve procedures alone. Despite a
higher risk profile in patients undergoing concomitant
tricuspid valve procedures, there was no difference in
survival compared with HMII alone. It would be interesting
to speculate on the mortality risks in patients with
significant valvular pathology who did not receive surgical
intervention on the valve. In addition, there was an
increased incidence of RV dysfunction in this group of
patients. Strategies to optimize RV function, as well as
further studies to develop selection criteria for concurrent
valve interventions, are important to further improve the
clinical outcomes in this group of patients.
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Dr Michael A. Acker (Philadelphia, Pa). Ranjit, great
presentation and very important data that you have presented
with your colleagues.
I think that for the first time that we know that it’s not a free
lunch, doing simultaneous valvular procedures while putting in
an LVAD. The bar to add additional valve procedures, especially
AV procedures has gotten less and less and now we know there
is a cost.
First question, I have 4, we know that INTERMACS class
consistently predicts short, intermediate, and long-term survival.
Did you look at that? And if not, why not? That was probably
available.
Second question, clearly the addition of an aortic valve
procedure, whatever procedure you do, results in increased
mortality, probably due to a mandatory ischemic time and, in
your article, which you didn’t show today, a significant increase
in bypass times. Given that, and a 2-year survival that, frankly,
is worse than the 2-year survival for INTERMACS 1, would you
recommend that unless there is moderate AI or greater not to touch
the aortic valve?
Third question, what’s your hypothesis for the poor 2-year
survival in the aortic valve group?
And finally, switching gears to the tricuspid valve, it’s a shame
you don’t have echo data, because there is still a controversy what
to dowithmoderate TR, and obviously it’s a marker for worse right
heart function. But is there any way to go back and actually
compare patients who had moderate TR who had a ring versusThe Journal of Thoracic and Cathose patients who did not have a ring and to see what their
long-term survival was?
Dr John. Thank you, Michael. I’ll start with your last question
first. Because of the lack of baseline data, it’s going to be hard to
compare who got a tricuspid valve or not. So the only message
I could take from this is it will be interesting to speculate about
the mortality and postoperative RV dysfunction of those patients
with significant valvular pathologies, such as moderate or severe
TR, who did not get a procedure.
I can tell you from our own personal experience that I’ve drifted
toward being more aggressive in fixing moderate to severe TR in
these patients compared with earlier in our experience.
We certainly didn’t have INTERMACS data for this study, but
that’s something we can go back and look at. However, I think
there is a slew of other important preoperative variables that do
reflect the higher risk in the patients getting a valvular procedure.
In the aortic valve procedures, certainly these patients were older
and the higher mortality is disturbing. I would also like to say that 3
or 4 studies have shown that the only reason why we fix an aortic
valve at the time of VAD implant is mild to moderate AI. It’s
certainly not harming the patient right now, but the worry is that
is it going to affect the patient in 1, 2, or 3 years down the road.
And as someone once told me, before we think of 3-, 5-, 10-year
survival, get the patient home first. So maybe we are being a little
too aggressive in fixing mild to moderate AI, and I think our goal
should be to identify risk factors to find out exactly which patients
develop severe AI and is that a mortality problem in these patients
after prolonged periods of time?
Dr Acker. What’s your hypothesis of why the survival is
dramatically different, not early on, but after that first period,
why are they dying at a faster rate than if they don’t have an aortic
valve procedure?
Dr John. The only thing I can think of is closure of the aortic
valve; is there a higher risk because of no flow in the LVOT, a
higher risk of thrombus developing around the aortic valve and
that leading to thromboembolic complications? However, I should
also state that there was no real reasons in terms of the adverse
events and mortality in terms of causes of death that could explain
the difference. So that still is a puzzle that needs to be sorted out.rdiovascular Surgery c Volume 147, Number 2 589
